A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model
Open Access
- 1 March 1998
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 160 (5) , 2531-2538
- https://doi.org/10.4049/jimmunol.160.5.2531
Abstract
Tumors that express tumor-specific antigens can maintain growth in an immunocompetent organism. Current hypotheses tend toward T cell anergy as a key component for the inhibition of immunoreactivity against such tumors. Anergy is thought to occur from hyperactive stimulation of the TCR in the absence of costimulation (costimulation leads to proliferation via IL 2 production). Subcutaneous injection of transgenic polyoma middle T transformed breast adenocarcinoma tumor cells (PyMT) in the hind flank of FVB/n mice results in the formation of tumor nodules at this site. We determined the MHC class I and class II, B7-1, and B7-2 expression in the tumor cells by flow cytometry and showed positive staining for only MHC class I. We show that a single E1-deleted adenovirus constructed to express both the costimulatory molecule B7-1 (murine) and human IL-2 genes (Ad5E1 mB7-1/human IL-2) elicits a very potent antitumor response when administered intratumorally. Ad5E1 mB7-1/human IL-2 induced rapid and complete regression (100%) of all tumors compared with Ad5 E1 mB7-1 (38%), Ad CAIL-2 (42%), and Ad5E1 dl70-3 (control vector) (0%). All mice that exhibited complete tumor regression were fully protected in tumor cell challenge experiments. The systemic immunity generated by intratumoral administration of the Ad vectors was associated with a strong anti-PyMT CTL response. These observations indicate that augmenting the immunogenicity of the tumor with coincident expression of B7-1 in combination with IL-2 may prove beneficial in direct tumor immunotherapy.Keywords
This publication has 60 references indexed in Scilit:
- B7-1 Amplifies the Response to Interleukin-2-Secreting Tumor Vaccines In Vivo, but Fails to Induce a Response by Naive Cells In VitroHuman Gene Therapy, 1995
- Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory responseEuropean Journal of Immunology, 1995
- The B7 and CD28 receptor familiesImmunology Today, 1994
- MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activationCell, 1994
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- A novel approach to the induction of specific cytolytic T cells in vivoResearch in Immunology, 1990
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977